NCT05368935View on ClinicalTrials.gov

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

77

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

September 4, 2022

Study Completion Date

September 9, 2022

Conditions

Renal ImpairmentRenal DiseaseKidney Disease

Interventions

DRUG

Nitazoxanide

500 mg Twice Daily for 7 days

Trial Locations (2)

32802

Orlando Clinical Research Center, Orlando

33014

Panax Clinical Research, Miami Lakes

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Genfit

INDUSTRY

NCT05368935 - Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects | Biotech Hunter | Biotech Hunter